Preconceptional optimization using CrMS cycle data establishes hormonal baselines, identifies correctable pathologies, and guides targeted supplementation before conception is attempted. Systematic preconceptional evaluation reduces early pregnancy loss and improves obstetric outcomes by ensuring the endocrine environment supports implantation and early embryonic development.
what does cervical mucus tell you about fertility before pregnancy, can cycle charting predict miscarriage risk, what does premenstrual spotting mean for fertility, Creighton Model FertilityCare System preconception, how does Peak Day relate to ovulation timing, limited mucus cycles and reproductive abnormalities, folic acid before pregnancy neural tube defects, low progesterone luteal phase spotting before period
Cite this article
Hilgers, T. W. (2004). Chapter 61: Preconceptional Care and the CREIGHTON MODEL System. The Medical and Surgical Practice of NaProTECHNOLOGY, 825-835.
Hilgers TW. Chapter 61: Preconceptional Care and the CREIGHTON MODEL System. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:825-835.
Hilgers, T. W. "Chapter 61: Preconceptional Care and the CREIGHTON MODEL System." The Medical and Surgical Practice of NaProTECHNOLOGY, 2004, pp. 825-835.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The sonographic ovulation classification is validated against targeted hormone profiles -- estradiol, LH, and serial post-Peak progesterone (P+3 through P+11) -- drawn at CrMS Peak-anchored time points rather than fixed calendar days. Hormone patterns corresponding to each sonographic category (e.g., absent LH surge in anovulation, progesterone rise without follicle rupture in LUF) confirm that ultrasound morphology reliably reflects the underlying endocrine disorder, establishing the biochemical legitimacy of the classification for clinical diagnosis.
NaProTECHNOLOGYCreighton Model FertilityCare SystemCervical eversion and ectropionChronic discharge charting and classification
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The Creighton Model's standardized daily vulvar observation system -- recording discharge color, consistency, quantity, and sensation -- allows chronic pathological discharges (persistent yellow or cloudy mucus, continuous post-Peak discharge, premenstrual brown bleeding, or refractory vulvovaginitis) to be distinguished from normal cyclical mucus patterns and tracked longitudinally as a diagnostic tool. NaProTECHNOLOGY uses chronic discharge patterns as biomarkers that prompt organism-specific cultures, targeted hormonal evaluation, ultrasound, and etiology-directed treatment -- including antimicrobials, cooperative hormone replacement, or fertility-sparing surgery -- rather than empirical cycle suppression.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
A CrMS-synchronized hormone sampling protocol is detailed in which progesterone, estradiol, and other reproductive hormones are drawn at cycle-phase-specific time points defined by the charted Peak Day rather than by fixed cycle day, producing a targeted hormone profile that accurately reflects luteal and follicular function. This Peak Day-referenced approach substantially improves the diagnostic sensitivity for luteal phase deficiency, follicular dysfunction, and other endocrine abnormalities that fixed-day sampling routinely misclassifies.
Bone HealthReproductive EndocrinologyFertility AwarenessNaProTECHNOLOGY
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Chronic anovulation and progesterone or estradiol deficiency identified through CrMS charting represent periods of suboptimal bone accrual in women of reproductive age, because both estradiol and progesterone contribute to skeletal maintenance -- estradiol through suppression of osteoclast activity and progesterone through osteoblast stimulation. NaProTECHNOLOGY uses longitudinal CrMS records of ovulatory status and hormone profiles as a bone-health risk screen, guiding cycle-synchronized bioidentical hormone replacement to restore normal estrogen-progesterone balance and potentially mitigate progression toward osteoporosis in women with chronic cycle-based endocrine deficiencies.